EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Protagonist Therapeutics, Inc.
EL7 Factor Analysis
How we score this
Overall98
Excellent — top fifth of the marketHigh FlyerF 3/9Better than 98% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
11
—17.8xBottom tier
▸
Growth
99
—7.1%Top tier
▸
Quality
88
—4.5%Top tier
▸
Safety
97
—2.6xTop tier
▸
Capital Return
48
—2.12%Around median
▸
Momentum
97
156.5%▲2.9%Top tier
▸
Sentiment
86
8▲3Top tier

Frequently Asked Questions

What is Protagonist Therapeutics, Inc. stock?▼

Protagonist Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Protagonist Therapeutics, Inc.?▼

You can buy Protagonist Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Protagonist Therapeutics, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Protagonist Therapeutics, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Protagonist Therapeutics, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

PTGX

PTGX Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. · NASDAQ
Market Closed
148.18
▲ ⁦+2.08%⁩ (+3.02)
Market Cap$9.5B
Beta1.79
52w Low52w High
54.50160.81
Last Week
⁦+1.44%⁩
Last Month
⁦+1.58%⁩
Last 3 Months
⁦+48.83%⁩
Last Year
⁦+141.22%⁩
Fair Value
Current price$148
Analyst target · 6 analysts
$172
⁦+16%⁩
See it undervalued
Range ⁦$121–$190⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 6 analysts setting price target
$169.38
⁦+14.3%⁩
Current Price $148.18·Median $171.50
Low
$121.00
High
$190.00
Current price
$148.18
Average target
$169.38
Street summary

Clear Increase in Price Target with High Dispersion

Bullish tilt

The consensus price target for PTGX rose over the last 30 days from 138.80 to 169.38, an increase of 30.58 points or 22.03%, while the number of analysts remained at 6. There was no change over the last 7 days, indicating that the improvement occurred earlier and is not currently ongoing. The current price is 145.94, while the target range is between 121 and 190, reflecting wide dispersion in estimates even though the consensus and median at 169.38 and 171.50 are above the current price.

As of 2026-09-08
Revisions momentum · 30d
⁦+5.0%⁩
Average rating
★ 4.23
Buy
Analyst coverage
13
Buy conviction
100%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
47%
Wide
Analyst ratings over time13 analysts rating
3
10
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.15 → 4.23
Recent analyst moves
  • = Reiterate2026-09-01
    Barclays
    Overweight
  • = Reiterate2026-08-31
    Wolfe Research
    Outperform
  • = Reiterate2026-08-31
    H.C. Wainwright
    Buy
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    —
    —
  • Forward P/E
    100.84x
    4.64x37.16x
    Very expensive
  • EV / EBITDA
    —
    —
  • FCF Yield
    0.5%
    -138.2%7.8%
    Strong
  • Revenue Growth YoY
    —
    —
  • EPS Growth YoY
    —
    —
  • Gross Margin
    —
    —
  • ROIC
    —
    —
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    —
    —
Financial Analysis
|